NASDAQ · VACHU
Financial Services
$14.50
Up+$1.00 (+7.41%)
Updated Sep 15, 2026, 6:21 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
VACHU does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning VACHU.
VACHU research
Company profile and research snapshot.
Voyager Acquisition Corp is a blank check company.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
GlobeNewswire Inc. · Sep 30, 2025
VERAXA Biotech and Secarna Pharmaceuticals announced a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for treating autoimmune and chronic immune diseases, combining their unique technology platforms.
GlobeNewswire Inc. · May 29, 2025
VERAXA Biotech, an emerging leader in cancer therapies, is attending the ASCO and BIO conferences to showcase its BiTAC platform and meet with potential partners and investors. The company is preparing to list on the NASDAQ later this year.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VACHU.
No results
No recent SID articles mention VACHU.
